MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06966700 |
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) |
RECRUITING | PHASE3 |
| NCT06765317 |
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma |
RECRUITING | PHASE2 |
| NCT05389423 |
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas |
RECRUITING | PHASE1 |
| NCT04139304 |
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma |
RECRUITING | EARLY_PHASE1 |
| NCT00092222 |
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity |
ACTIVE_NOT_RECRUITING | PHASE2 |
